Drug Trial Radar · NCT05949606
A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
95
Actual
Start
Oct 30, 2023
Primary completion
Dec 2026
Study completion Dec 2027
Sponsor
- Lead sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase Ib: To observe the safety and tolerability of the combination of SI-B001 and SI-B003, and to determine the recommended dose of phase II clinical study (RP2D) in the indication of locally advanced or metastatic non-small cell lung cancer. Phase II: To evaluate the efficacy of SI-B001+SI-B003 combination with or without chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer.
Conditions
- Non-small Cell Lung Cancer
Interventions
SI-B001Drug
Administration by intravenous infusion
SI-B003Drug
Administration by intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib/II: Recommended Phase II Dose (RP2D)Time frame: Up to approximately 24 months
- Phase Ib/II: Objective response rate (ORR)Time frame: Up to approximately 24 months
- Phase Ib: Dose Limited Toxicity (DLT)Time frame: Up to approximately 24 months
- Phase Ib: Maximum Tolerated dose (MTD) or maximum administered dose (MAD)Time frame: Up to approximately 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.